Marco de Morpurgo

Partner

GLOBAL CO-CHAIR, LIFE SCIENCES SECTOR

marco.demorpurgo@dlapiper.com

Rome

T: +39 06 68 880 1

F: +39 06 68 880 201

Marco de Morpurgo focuses on government regulation of the Life Sciences industry. He helps companies doing business in the EU navigate the complex regulatory structures governing the sector, counseling such clients on regulatory strategies and compliance matters.

His practice covers the regulation of pharmaceuticals, biotechnologies, medical devices, and other health-related regulated products in the EU. He provides strategic advice on a broad range of regulatory issues, including clinical trials, product approvals, market access, promotion and advertising, post-market obligations, as well as on industry-specific ethical and behavioral rules. Most of Marco's work is multi-jurisdictional and he has broad experience assisting clients manage regulatory divergence within the EU and globally.

He regularly speaks and writes on Life Sciences topics. He is a member of the Editorial Board of the European Pharmaceutical Law Review and teaches Life Sciences Law at HEC Paris.

LANGUAGES SPOKEN

- Italienisch
- Englisch
- Französisch
- Spanisch

VITA

Zulassung

- Avvocato admitted to the Rome Bar
- Avocat admitted to the Paris Bar

RELATED SERVICES

- Intellectual Property and Technology

RELATED SECTORS

- Life Sciences

LANGUAGES SPOKEN

Italienisch Englisch Französisch Spanisch

- Abogado registered with Ilustre Colegio de Abogados de Madrid
- Attorney-at-Law zugelassen beim Supreme Court von New York

Berufserfahrung

- Before joining DLA Piper, Marco worked with leading international law firms in Brussels, London and Paris.

Ausbildung

- University of Milan, Ph.D., Comparative Law
- Harvard Law School, LL.M.
- IUC Turin, M.Sc., Comparative Law, Economics & Finance
- University of Trieste, Law degree

AKTUELLES

Publikationen

Telehealth around the world: A global guide

19 November 2020

This Global Guide provides an overview of the current state of telehealth regulations worldwide and assists readers to identify the opportunities, challenges and risks, on a country-by-country basis.

Digital Therapeutics - evolution and entry into mainstream healthcare

18 September 2020
Research undertaken by DLA Piper's Life Sciences sector in conjunction with The Lawyer seeks to understand the current developments in the field of digital therapeutics, looking at key questions that need to be addressed if these products are to become mainstream components of health systems across the world.

Klinische Studien während der COVID-19-Pandemie: Ein globaler Leitfaden - Ausgabe 2: Aktualisiert und erweitert

2 July 2020
Die Folgen der COVID-19-Pandemie entwickeln sich weiterhin dynamisch. Während einige Länder beginnen, die Lockdown-Maßnahmen wieder zu lockern, halten andere an ihren bisherigen Maßnahmen fest oder führen sogar weitere Beschränkungen ein. Diese Maßnahmen wirken sich auch weiterhin weltweit auf die Durchführung von klinischen Studien aus. Pharmazeutische Unternehmen müssen sich teilweise noch größeren Herausforderungen stellen als bislang, um die Kontinuität von klinischen Studien weiterhin zu gewährleisten. In dieser aktualisierten Ausgabe des Leitfadens, die von unserer globalen Life Sciences Praxisgruppe verfasst wurde, stellen wir die regulatorischen Entwicklungen in mehr als 50 Ländern dar, darunter Neueinträge zu Ländern in Afrika und im asiatisch-pazifischen Raum.

Klinische Studien während der COVID-19-Pandemie: Ein globaler Leitfaden

17 April 2020
Die beispiellosen Folgen der COVID-19-Pandemie wirken sich auf globaler Ebene auch auf die Durchführung von klinischen

Studien aus. Pharmazeutische Unternehmen müssen sich einer Vielzahl von Herausforderungen stellen, um die Kontinuität von klinischen Studien zu gewährleisten. Zahlreiche Länder haben lokale Maßnahmen eingeführt, die unter anderem den Zugang von Patienten zu Krankenhäusern und sonstigen Prüfzentren beeinträchtigen. Darüber hinaus werfen insbesondere die begrenzte Verfügbarkeit von medizinischem Personal und Unterbrechungen in globalen Herstellungs- und Lieferketten zahlreiche Fragen zur Sicherstellung der Bereitstellung von Prüfpräparaten (IMPs) und Möglichkeit der Änderung von Prüfprotokollen auf.

European Commission proposes one-year postponement of MDR application date

8 April 2020
Following an informal heads-up on 25 March 2020, today the European Commission adopted a proposed regulation to postpone by one year the date of application of the Medical Devices Regulation (Regulation (EU) 2017/745, “MDR”). If enacted, the Medical Device Directive (Directive 93/42/EEC) and implementing legislation of the EU member states will continue to apply as far as they have not yet been amended.

Italian Medicines Agency tackles challenges related to clinical trial management during COVID-19 emergency

20 March 2020
In the recent UK Budget, and subsequent announcements, several initiatives have been introduced to support businesses in response to coronavirus COVID-19, but as yet there are no generally applicable leniencies on when tax has to be paid or returns filed. Read to find out more.

Italian DLA Piper Intellectual Property & Technology Legal Predictions for 2020

28 February 2020
DLA Piper Italian Intellectual Property & Technology practice group has published its Legal Predictions for 2019. These take a look back at what happened during 2019 and illustrate the key changes that are expected in 2020.

- EU SPC Manufacturing Waiver Becomes Effective: What Can Industry Expect?, European Pharmaceutical Law Review, Volume 3, Issue 3 (2019)
- The Sun Also Rises in Italy: New Statutory Transparency Requirements Expected under the Proposed Italian Sunshine Act, European Pharmaceutical Law Review, Volume 2, Issue 4 (2018)
- Italy Reforms Clinical Trial Rules, European Pharmaceutical Law Review, Volume 2, Issue 1 (2018)

Seminare und Veranstaltungen

Vergangene

Anti-COVID devices: a comparison between the UK and Italy

29 September 2020
Webseminare

NEWS

DLA Piper launches global cannabis practice

21 February 2020

DLA Piper has launched a dedicated global cannabis practice that will sit as a sub-group under its Life Sciences sector. The decision to formalise the firm's offering follows the completion of a significant number of global deals in the sector that have amounted to over USD8 billion to date, as well as a number of large cannabis regulatory advisory mandates.